Table 2.
Baseline characteristics of the heart failure genetic registry overall and stratified by rs9303504 genotype
| rs9303504 genotype | |||||
|---|---|---|---|---|---|
| Baseline characteristics | All patients (n = 951) |
CC (n = 307; 32%) |
CG (n = 451; 48%) |
GG (n = 193; 20%) |
*p-value |
| Female | 341 (35.9%) | 107 (34.9%) | 161 (35.7%) | 73 (37.8%) | 0.793 |
| Self-reported African-American race | 481 (50.6%) | 169 (55.1%) | 227 (50.3%) | 85 (44.0%) | 0.056 |
| Age (years) | 68.3 ± 11.7 | 67.7 ± 11.6 | 68.4 ± 11.4 | 69.0 ± 12.4 | 0.445 |
| Left ventricular ejection fraction (%) | 34.7 ± 10.9 | 34.9 ± 10.9 | 34.4 ± 11.0 | 35.2 ± 10.8 | 0.691 |
| Ischemic etiology | 416 (43.7%) | 121 (39.4%) | 202 (44.8%) | 93 (48.2%) | 0.130 |
| Hypertension | 855 (89.9%) | 282 (91.9%) | 400 (88.7%) | 173 (89.6%) | 0.362 |
| Chronic obstructive pulmonary disease | 220 (23.1%) | 73 (23.8%) | 95 (21.1%) | 52 (26.9%) | 0.255 |
| Chronic kidney disease | 222 (23.3%) | 79 (25.7%) | 107 (23.7%) | 36 (18.7%) | 0.184 |
| Atrial fibrillation | 267 (28.1%) | 94 (306%) | 119 (26.4%) | 54 (28.0%) | 0.444 |
| Stroke/transient ischemic attack | 122 (12.8%) | 36 (11.7%) | 65 (14.4%) | 21 (10.9%) | 0.368 |
| Diabetes | 399 (42.0%) | 120 (39.1%) | 199 (44.1%) | 80 (41.5%) | 0.381 |
| Body mass index (kg/m2) | 31.0 ± 7.3 | 31.4 ± 7.5 | 30.7 ± 7.3 | 30.9 ± 7.3 | 0.430 |
| Systolic blood pressure (mmHg) | 129 ± 23 | 130 ± 24 | 129 ± 23 | 129 ± 20 | 0.885 |
| Heart rate (beats per minute) | 71.2 ± 12.9 | 72.1 ± 13.8 | 70.8 ± 12.3 | 70.6 ± 12.6 | 0.312 |
| NT pro-BNP (pmol/L) | 368 ± 384 | 370 ± 387 | 389 ± 406 | 315 ± 319 | 0.082 |
| Serum creatinine (mg/dL) | 1.29 ± 0.93 | 1.23 ± 0.59 | 1.38 ± 1.22 | 1.15 ± 0.47 | 0.014 |
| MAGGIC risk score (w/o beta-blocker) | 18.2 ± 7.3 | 17.8 ± 7.2 | 18.3 ± 7.4 | 18.3 ± 7.0 | 0.661 |
| 1st principal component | 0.0007 ± 0.035 | 0.0019 ± 0.038 | -0.0002 ± 0.037 | 0.0003 ± 0.026 | 0.726 |
| 2nd principal component | 0.0038 ± 0.042 | 0.0055 ± 0.058 | 0.0028 ± 0.031 | 0.0034 ± 0.032 | 0.672 |
| 3rd principal component | −0.0002 ± 0.032 | 0.0018 ± 0.040 | 0.0008 ± 0.026 | −0.0057 ± 0.028 | 0.023 |
| Beta-blocker exposure | 0.27 ± 0.29 | 0.26 ± 0.29 | 0.28 ± 0.29 | 0.28 ± 0.31 | 0.663 |
| Any beta-blocker exposure | 623 (65.5%) | 204 (66.5%) | 288 (63.9%) | 131 (67.9%) | 0.565 |
| Any ACEI/ARB exposure | 580 (61.0%) | 191 (62.2%) | 271 (60.1%) | 118 (61.1%) | 0.840 |
| Length of follow-up (days) | 1104 ± 701 | 1056 ± 714 | 1138 ± 721 | 1103 ± 627 | 0.286 |
| Deaths | 239 (25.1%) | 91 (29.6%) | 100 (22.2%) | 48 (24.9%) | 0.066 |
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; MAGGIC: Meta-Analysis Global Group in Chronic Heart Failure risk score; NT pro-BNP: N-terminal pro b-type natriuretic peptide
*
p-value is for difference among the three genotypes. Bolded p-values indicate p < 0.05.